# EyePoint, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/EyePoint, Inc.). ## Overview EyePoint, Inc. is a clinical-stage biopharmaceutical company focused on retinal diseases, using its proprietary Durasert E bioerodible implant platform to deliver drugs inside the eye over extended periods. Its lead candidate, DURAVYU, is being developed for wet age-related macular degeneration and diabetic macular edema, while the company also commercializes legacy ophthalmic products and earns collaboration and royalty revenue. ## Products & services • DURAVYU™ sustained-delivery treatment for wet AMD and DME • Durasert E™ bioerodible intraocular drug-delivery platform • YUTIQ® commercial product rights and related royalties • DEXYCU® commercial ophthalmic product • EYP-2301 / razuprotafib retinal disease pipeline program • License and collaboration agreements with partners - **Clinical-stage pipeline** (55%) — Investigational retinal disease therapies centered on DURAVYU and EYP-2301. - **Commercial ophthalmic products** (20%) — Legacy marketed eye-disease products including YUTIQ and DEXYCU. - **Royalty income** (20%) — Royalties from partners' net sales under license and collaboration agreements. - **License and collaboration revenue** (5%) — Deferred revenue recognition and milestone-related collaboration income. - DURAVYU™ for wet AMD and diabetic macular edema - Durasert E™ bioerodible sustained-release eye implant platform - YUTIQ® commercial product rights and royalty income - DEXYCU® ophthalmic product and related commercialization - EYP-2301 / razuprotafib pipeline for retinal disease - License and collaboration agreements with pharma partners ## Customers EyePoint sells to ophthalmologists, retina specialists, and the healthcare systems that use its commercial eye products, while its development-stage programs are aimed at patients with serious retinal diseases such as wet AMD and DME. A meaningful part of revenue also comes indirectly from partners and licensees through royalty and collaboration arrangements rather than direct end-customer sales. - **Retina specialists and ophthalmologists** (primary) — They prescribe or administer EyePoint's eye-disease therapies because the products target chronic retinal conditions requiring repeated treatment. - **Pharmaceutical partners and licensees** (primary) — They buy or license product rights and generate royalty streams tied to their commercial sales. - **Healthcare systems and clinics** (secondary) — They purchase commercial ophthalmic products for patient treatment and procedural use. - **Patients with retinal disease** (primary) — They are the end beneficiaries of DURAVYU and other retinal therapies, driving physician demand. - Retina specialists treating wet AMD and diabetic macular edema - Ophthalmology practices using commercial eye-disease products - Pharma partners paying royalties on licensed product sales - Healthcare providers seeking longer-acting intraocular therapies - Patients with chronic retinal disease needing sustained treatment ## Geography EyePoint is headquartered in Watertown, Massachusetts and operates a commercial manufacturing facility in Northbridge, Massachusetts, so its core operations are concentrated in the United States. The filings also reference international partner relationships, but the excerpts provided do not disclose a country-by-country revenue split. - Headquartered in Watertown, Massachusetts - Commercial manufacturing facility in Northbridge, Massachusetts - U.S.-based clinical development and corporate operations - International partner agreements create non-U.S. exposure - No country-level revenue split disclosed in the excerpts ## Strategy EyePoint's strategy is to convert its Durasert E delivery platform into a differentiated retinal-disease franchise, with DURAVYU as the lead asset in late-stage trials for two large markets. Near term, the company is balancing clinical execution with cash preservation, while also monetizing legacy products and partner agreements to support funding needs. - **Complete and read out DURAVYU Phase 3 trials** (short-term) — Late-stage data is the main value driver and determines regulatory and commercialization prospects. - **Preserve liquidity and access capital** (short-term) — Clinical-stage development requires ongoing funding before product approval and commercialization. - **Build a differentiated retinal platform** (medium-term) — Longer-duration delivery and multi-mechanism therapy can improve efficacy and dosing convenience versus competitors. - Advance DURAVYU through Phase 3 trials in wet AMD and DME - Differentiate with sustained intraocular delivery and multi-mechanism action - Use legacy products and royalties to help fund development - Expand pipeline optionality with EYP-2301 and related programs - Manage capital carefully while funding clinical and regulatory work ## Risks The company faces the usual clinical-stage biotech risks: trial failure, regulatory delay, and the possibility that competitors reach market first with better efficacy or dosing convenience. It also has company-specific exposure to a DOJ investigation tied to sales and marketing practices, dependence on third-party partners and IP licenses, and potential cybersecurity and trade-secret risks that could disrupt operations or damage its competitive position. - **Clinical trial failure or delay for DURAVYU** [high] — The lead asset is still investigational, so negative data or slower enrollment would directly reduce pipeline value. - **DOJ investigation into sales and marketing practices** [high] — A negotiated resolution may require payments, compliance undertakings, or other restrictions that consume cash and management time. - **Dependence on Equinox Science license and vorolanib supply** [high] — Loss of license rights or API access would impair the core DURAVYU program. - **Competitive pressure in retinal disease** [medium] — Large incumbents and biosimilars can offer earlier, cheaper, or more established therapies. - **Cybersecurity and third-party vendor disruption** [medium] — Clinical and patient data, as well as outsourced operations, create breach and continuity risk. - DURAVYU may fail in Phase 3 or miss efficacy/safety expectations - DOJ investigation could lead to settlement, penalties, or oversight - Dependence on licensed IP and API supply for vorolanib - Competition from established wet AMD and DME therapies - Cybersecurity or data breaches could disrupt trials and operations - Need for external funding if clinical spend rises or timelines slip ## Accounting Revenue recognition is judgmental because the company records product sales, collaboration revenue, and royalties under different timing rules, including deferred revenue and royalty true-ups. Clinical trial spending is also sensitive to estimates in outsourced agreements, while commercial revenue includes variable consideration and allowances that can move reported results quarter to quarter. - **Revenue recognition for royalties and collaborations** — Can create timing swings in reported revenue - **Variable consideration and product sales allowances** — Affects net product sales and gross-to-net deductions - **Accruals for outsourced clinical trial agreements** — Can shift R&D expense between periods - **Deferred royalty true-ups** — May cause immaterial but recurring revenue adjustments - Royalty income is recognized when partners report underlying sales - Deferred collaboration revenue can shift timing of reported revenue - Product sales net of allowances affect commercial revenue - Outsourced clinical trial costs rely on accrual estimates - Variable consideration reserves can change reported revenue --- *Last updated: 2026-04-28T20:05:55.554464+00:00*